VEGF controls microglial phagocytic response to amyloid-β

Priscille de Gea1, Sarah Benkeder1, Pauline Bouvet1

  • 1Laboratory MeLIS, Institut Neuromyogène, Synaptopathies and Autoantibodies, INSERM U1314, CNRS UMR 5284, Université Claude Bernard Lyon 1, Lyon, France.

PubMed

Insights

Vascular Endothelial Growth Factor (VEGF) enhances microglial cells' ability to clear toxic amyloid-beta oligomers (Aβo) in Alzheimer's disease (AD). This discovery suggests VEGF could restore microglial function in AD.

Area of Science:

  • Neuroscience
  • Immunology
  • Molecular Biology

Background:

  • Microglial cells are crucial in Alzheimer's disease (AD) pathogenesis due to impaired amyloid-beta (Aβ) clearance.
  • Amyloid-beta oligomers (Aβo) are the most neurotoxic forms, causing synaptic damage.
  • Vascular Endothelial Growth Factor (VEGF) has shown potential in counteracting Aβo effects and promoting microglial migration.

Purpose of the Study:

  • To investigate the influence of VEGF on microglial phagocytic response to Aβ.
  • To elucidate the molecular mechanisms underlying VEGF's effect on microglial Aβ clearance.

Main Methods:

  • Utilized in vitro and ex vivo models of amyloid accumulation.
  • Assessed microglial phagocytosis of Aβ oligomers.
  • Investigated the role of α-secretase activity and TREM2 cleavage in microglial cells.

Main Results:

  • VEGF significantly increases the phagocytosis of Aβ oligomers by microglial cells.
  • VEGF modulates α-secretase activity, leading to enhanced cleavage of TREM2 (Triggering Receptor Expressed on Myeloid cells 2).
  • Soluble TREM2 (sTREM2) also promotes microglial phagocytosis of Aβ oligomers.

Conclusions:

  • VEGF acts as a novel regulator of Aβ clearance by enhancing microglial phagocytosis.
  • The findings suggest VEGF's potential therapeutic role in restoring impaired microglial function in Alzheimer's disease.

Related Concept Videos